RobertB.BhisitkulMD

Ophthalmology • San Francisco, CA

Professor, Ophthalmology, UCSF School of Medicine

Join to view full profile

Dr. Bhisitkul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bhisitkul's full profile

Already have an account?

Office
400 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-353-2402

Fax+1 415-353-2713

Education & Training

Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Transitional Year, 1992 - 1993
Stanford University School of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 1998 - 2026
MA State Medical License 1996 - 1999
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery Start of enrollment: 2008 Apr 01
Terminated
Not Applicable
Seven Year Update of Macular Degeneration Patients Start of enrollment: 2010 Dec 01
Completed

Publications & Presentations

PubMed

2 citations
Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vis...
Robert B Bhisitkul, Peter A Campochiaro, Steven Blotner, Carlos Quezada-Ruiz, Mimi Liu
The British Journal of Ophthalmology. 2024-08-22
Subretinal hyperreflective material in regions of atrophy and fibrosis in eyes with neovascular age-related macular degeneration.
Sophiana Lindenberg, Muneeswar G Nittala, Aditya Verma, Malinda E C Fitzgerald, Swetha B Velaga
Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2024-05-27
3 citations
Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study.
Daniel S Pereira, Kazumasa Akita, Robert B Bhisitkul, Toshiaki Nishihata, Yusuf Ali
Eye. 2024-04-01

Press Mentions

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaMarch 23rd, 2023
UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the EyeOctober 11th, 2022
UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye DiseaseNovember 9th, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow